Capricor Therapeutics, INC.: directors' dealings · United States · SEC (Form 4)

About Capricor Therapeutics, INC.

Capricor Therapeutics, Inc. is a US-listed biopharmaceutical company trading on the NASDAQ in the United States. Headquartered in San Diego, California, the company focuses on cell-based and exosome-based therapeutics for rare diseases, with an emphasis on high-unmet-need neuromuscular and inflammatory conditions. Capricor’s corporate identity has been shaped by a science-driven development model built on academic partnerships, and by a strategy that prioritizes differentiated biologics rather than large-volume commercial drugs. The company’s evolution into its current public structure followed a merger completed in 2013, and it has since remained a development-stage biotech with increasing industrial readiness as it moves closer to potential commercialization. The company’s lead asset is Deramiocel, formerly known as CAP-1002, a cell therapy being developed primarily for Duchenne muscular dystrophy-associated cardiomyopathy. Capricor is positioning Deramiocel as a potentially disease-modifying therapy aimed at both cardiac and functional outcomes, which is central to its investment thesis. Beyond Duchenne, the company has signaled broader neuromuscular potential, including Becker muscular dystrophy, and has also highlighted exosome-related science and anti-fibrotic, immunomodulatory mechanisms as part of its platform. This gives Capricor a relatively focused but scientifically differentiated pipeline, anchored in rare disease biology and translational medicine. From a competitive perspective, Capricor operates in a niche but highly competitive segment of biotechnology. It is not a broad pharma company; instead, it competes with other advanced-therapy developers pursuing gene, cell, and regenerative approaches in rare disease. That creates a binary, high-upside profile, but also exposes the company to clinical, regulatory, manufacturing, and financing risks that are typical of specialty biotech. Its San Diego manufacturing footprint is strategically important because commercial success in cell therapy depends not only on clinical efficacy but also on GMP manufacturing consistency and supply-chain execution. Recent company developments have been meaningful. In 2025 and 2026, Capricor reported continued regulatory progress on the Deramiocel BLA, with the FDA review active and a PDUFA target action date of August 22, 2026. The company also cited positive HOPE-3 Phase 3 data, including functional and cardiac endpoints, which helped support the program’s clinical profile. On the operational side, Capricor expanded manufacturing space at its San Diego headquarters to prepare for a possible launch. Financially, the company strengthened its balance sheet through capital raises in 2025, improving runway into 2027 based on management disclosure. For international investors, CAPR is best viewed as a NASDAQ-listed United States biotech story driven by clinical milestones, regulatory execution, and the transition from late-stage development to potential commercialization.